|
Mella O, Howell A. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111116, 2001. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32: 10311036, 1983. Jordan VC, Collins MM, Rowsby L, Prestwich GA. monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J Endocrinol 75: 305316, 1977. MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, Jordan VC. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 60: 50975105, 2000. Liu H, Park WC, Bentrem DJ, McKian KP, de los Reyes A, Loweth JA, Schafer JM, Zapf JW, Jordan VC. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem 277: 91899198, 2002. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19: 490497, 2000. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De los Reyes A, Wing L, Jordan VC. Apoptotic action of 17 beta-estradiol in raloxifene resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95: 15861596, 2003. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9: 659669, 1995. Jordan VC, MacGregor Schafer JI, Levenson AS, Liu H, Pease KM, Simons LA, Zapf JW. Molecular classification of estrogens. Cancer Res 61: 66196623, 2001. Gust R, Keilitz R, Schmidt K. Investigations of new lead structures for the design of selective estrogen receptor modulators. J Med Chem 44: 19631970, 2001. Bentrem D, Fox JE, Pearce ST, Liu H, Pappas S, Kupfer D, Zapf JW, Jordan VC. Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res 63: 74907496, 2003. Jordan VC, Mittal S, Gosden B, Koch R, Lieberman ME. Structureactivity relationships of estrogens. Environmental Health Perspectives NIH special issue ; 61: 97110, 1985. Liu H, Lee ES, De los Reyes A, Zapf JW, Jordan VC. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 61: 36323639, 2001. Jiang SY, Jordan VC. Growth regulation of estrogen receptor negative breast cancer cells transfected with cDNA's for estrogen receptor. J Natl Cancer Inst 84: 580591, 1992. Levenson AS, Jordan VC. Transfection of human estrogen receptor ER ; cDNA in ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 51: 229239, 1994.
176. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black1 DM. Pretreatment bone turnover and fracture efficacy of alendronate: The Fracture Intervention Trial. J Bone Miner Res 18: S55, 2003 177. Seibel MJ, Naganathan V, Barton I, Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19: 323-329, 2004 Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 45: 13591368, 1999 Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42: 947-954, 1996 Risteli J, Niemi S, Kauppila S, Melkko J, Risteli L. Collagen propeptides as indicators of collagen assembly. Acta Orthop Scand Suppl 266: 183-188, 1995 Peris P, Alvarez L, Monegal A, Guanabens N, Duran M, Pons F, Martinez de Osaba MJ, Echevarria M, Ballesta AM, Munoz-Gomez J. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 25: 349-353, 1999 Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S, Elomaa I. Aminoterminal propeptide of type I procollagen PINP ; correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and postmenopausal non metastatic breast cancer patients. Br J Cancer 78: 240245, 1998 Dominguez Cabrera C, Sosa Henriquez M, Traba ML, Alvarez Villafane E, de la Piedra C. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporosis International. 8: 147-151, 1998 Suvanto-Luukkonen E, Risteli L, Sundstrm H, Penttinen J, Kauppila A, Risteli J. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy. Clin Chim Acta 266: 105-116, 1997 Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34: 344-351, 2004 Erikson EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 8: 127-132, 1993 Kylml T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastates with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 29: 821-825, 1993 Vlimki MJ, Thtel R, Jones JD, Peterson JM, Riggs BL. Bone resorption in healthy and osteoporotic postmenopausal women: comparison of markers for serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross links. Eur J Endocrinol 131: 258262, 1994 Hassager C, Jensen LT, Podenphant J, Thomsen K, Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 54: 30-33, 1994 Mincey BA, Moraghan TJ, Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic Proceedings 75: 821-829, 2000 Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 43: 183-190, 1997 Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: the International Breast Cancer Study Group. Ann Oncol 1: 183-188, 1990 Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U. Tenyear experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95-115, 1985 Padmanabhan N, Wang DY, Moore JW, Rubens RD. Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer 23: 745-748, 1987 Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19: 3306-3311, 2001.
Positive breast cancer7 and reduces the risk of contralateral breast cancer.8, 9 Three trials10-12 have tested tamoxifen for primary prevention of breast cancer. Two found no effect, but the study with the most participants, the Breast Cancer Prevention Trial BCPT ; , 12 reported that tamoxifen reduced breast cancer risk by about 50% among women who had a high risk of breast cancer because of age older than 60 years ; or a combination of other risk factors. However, most breast cancers occur in women who are not identified to be at increased risk.13 To substantially reduce the rate of breast cancer in the whole population, a preventive intervention would need to be safe and effective for long periods to be acceptable for use among women who have an average or low risk of breast cancer. In addition to increasing the risk of thromboembolic disease, tamoxifen increases the risk of endometrial cancer, 12, 14 which may limit its use for primary prevention of breast cancer. Raloxifene hydrochloride is a selective estrogen receptor modulator, chemically distinct from tamoxifen and estradiol, that binds to estrogen receptors to competitively block estrogen-induced DNA transcription in the breast and endometrium.15, 16 In animal studies, raloxifene inhibits estrogen-stimulated.
Persunas che tschertgan abitaziuns possian chattar per els e per lur famiglia in'abitaziun adattada per cundiziuns acceptablas; uffants e giuvenils sco er persunas en la vegliadetgna da lavur possian giudair ina scolaziun ed instrucziun sco er ina furmaziun supplementara tenor lur abilitads; uffants e giuvenils vegnian promovids en lur svilup a persunas independentas e socialmain responsablas e vegnian sustegnidas en lur integraziun sociala, culturala e politica.
Table 3.--Effects of Raloxifene, HRT, and Placebo on Coagulation Factors in Healthy Postmenopausal Women.
From unhealthy competition from spurious drug manufacturers. With the globalisation of pharmaceutical products, the industry will face a surfeit of risks, product liabilities, regulatory issues and patent litigations. The rate of growth in the last two years, in the domestic pharmaceutical industry, has declined to a single-digit i.e. in the range of 7-8 per cent p.a. New Intellectual Property Rights IPR ; permitting product patent and long pending liberalisation of drug-price control are two major developments expected to affect the industry. Outlook The Company is well positioned in the emerging business scenario to enhance market share in the domestic market and in selected international markets. It is also poised to enhance shareholder value by investing more on R&D front and achieving higher levels of productivity and efficiency in all areas of operations. Financial performance The Company has registered a total income of Rs. 626.40 crore for the year under review as compared to Rs. 575.03 crore for and efavirenz.
The UMMG has used funds under the Other Tobacco-Related Diseases Research Grant OTRD ; to support faculty to conduct health services research, translational research, and clinical research. Johns Hopkins Institutions JHI ; Under the CRFP, DHMH awards funds to the Johns Hopkins Institutions JHI ; for a cancer research grant each year. DHMH has awarded JHI a total of , 749, 000 under the CRFP for cancer research grants from fiscal year 2001 to 2005 See Table 2 ; . Table 2 Funds Awarded to the Johns Hopkins Institutions for Cancer Research Grants under the CRFP Fiscal Year 2001 2002 2003 Total Amount Awarded , 750, 000 , 000, 000 , 000, 000 , 590, 000 , 409, 000 , 749, 000.
Raloxifene: a new choice for treating and preventing osteoporosis articles for medical professionals from the cleveland clinic article written 11 01 2001 published online 02 11 2004 spineuniverse is a world leading site for back and neck information and sustiva.
Raloxifene online
Tablet manufacturing at orion's plant in vallila, helsinki, in the1940s.
Were present deep within the myometrium, sometimes extending to, but not penetrating, the serosa. Notable was the disordered arrangement of the smooth muscle of the myometrium. In contrast to controls where smooth muscle fibers were arranged in uniform concentric layers around the endometrium, in tamoxifen- and toremifenetreated mice, this zone comprised irregular smooth muscle bundles interspersed with collagen and often penetrated by prominent blood vessels. The smooth muscle changes were more extensive than the zones of abnormal glands. This suggests that the penetration of endometrial glands might follow the changes to myometrium rather than precede them. These areas of altered smooth muscle organization were associated with a scattering of polymorphonuclear leukocytes, notably eosinophils. The presence of eosinophils has been reported in both human endometriosis and carcinoma where it has been postulated that they are involved in general tissue-remodeling.13 It is of note that there was neither evidence of vaginal adenosis nor the extension of the oviduct epithelium through the muscularis described in stilbestroltreated CD-1 mice by Newbold and colleagues14 in the treated mice. The histological alterations and principle genetic changes, which occurred in the neonatal uterus immediately after treatment with tamoxifen and toremifene, provide additional support for the concept that the primary derangement of the uterine mesenchymal tissue differentiation is the basis for the development of adenomyosis. At 6 days the uterine body in mice treated with tamoxifen and toremifene, but not raloxifene or estradiol, was devoid of the normal developing layers of smooth muscle but retained histological appearances and ER status of endometrial stroma. In addition, some unusual patterns of differentiation were noted, particularly the presence of lipocytes in the outermost parts of the uterus, features resembling adipose tissue of the developing mesenteric tissue in the surrounding mesenchyme. In contrast to the major changes in mesenchymal differentiation, alterations to histological and receptor status in endometrial glandular tissue, produced by treatment, were modest. This was reflected by the lack of major alteration in the ER gene in endometrial glandular tissues. Not only did endometrial glands show no major differences in ER status, the endometrium itself continued to show regular cyclical alterations in treated groups similar to those in controls. These data suggest that the functional status of the endometrial glandular tissue is not greatly altered in adenomyosis. In the present study, no cystic ovaries were observed and corpora lutea were seen in all of the treatment groups. This contrasts to previous findings at 14 to months after dosing where corpora lutea were absent when tamoxifen was given subcutaneously on days 1 to 5 newborn CD-1 mice.15 Although the conventional view is that adenomyosis represents down-growth of endometrial glands and stroma into the myometrium with secondary local tissue response, 1 other recent evidence also underlines the importance of mesenchymal tissue in the development of adenomyosis. It has been postulated, based on histopathological and immunocytochemical analysis of the and vaseretic.
Other income expenses ; 1 ; assets used for its business operations with respect to distribution rights for imported goods of 13, 059 million 2, 047 thousand ; in the pharmaceutical division, the company recognized the entire impairment loss on these distribution rights as other expenses because the company expects to have negative cash flows on these imported goods due to a decrease in profitability resulting from their sluggish sales.
It does not tell us which drug is better and ethambutol.
Sign in create free account home product list online doctor testimonials order status live support faq's cart is empty view cart my wish list mens health sildenafil citrate generic cialis tadalafil ; generic propecia finasteride ; womens health generic clomid clomiphene citrate ; generic ovral norgestrel + ethinyl estradiol ; quit smoking generic zyban sr bupropion sr ; pain relief celecoxib generic soma carisoprodol ; generic ultram tramadol ; generic zanaflex tizanidine ; allergy generic allegra fexofenadine ; cetirizine generic clarinex desloratadine ; generic singulair montelukast ; gastric generic nexium esomeprazole ; generic prilosec omeprazole ; generic prevacid lansoprazole ; antidepressants generic wellbutrin sr bupropion sr ; generic prozac fluoxetine ; sertraline generic celexa citalopram ; generic paxil paroxetine ; generic effexor xr venlafaxine xr ; antibiotic brand amoxil amoxicillin ; generic amoxicillin amoxicillin ; generic cipro ciprofloxacin ; doxycycline azithromycin generic bactrim sulphamethoxazole ; osteoporosis generic evista raloxifene ; generic fosamax alendronate ; migraine generic imitrex sumatriptan ; lipid lowering generic zocor simvastatin ; atorvastatin generic pravachol pravastatin ; blood pressure generic avapro irbesartan ; amlodipine generic toprol xl metoprolol ; brand lasix generic tenormin atenolol ; hydrochlorothiazide generic lopressor metoprolol ; diabetes generic amaryl glimepiride ; generic glucophage metformin ; glipizide xl alcoholism generic antabuse disulfiram ; antifungal fluconazole generic flagyl metronidazole ; generic lamisil terbinafine ; generic sporanox itraconazole ; anticonvulsant generic topamax topiramate ; thyroid generic synthroid levothyroxine ; blood thinner generic coumadin warfarin ; antiplatelet generic plavix clopidogrel ; generic flagyl 400 mg category : antifungal contents : metronidazole 400 mg drug class: what is flagyl and why is it prescribed.
| An alpha-adrenergic blocker; or b ; For use in combination therapy when monotherapy with an alpha-blocker is not sufficient. 2. Pegfilgrastim, Solution, 10mg mL Neulasta Amgen Canada Inc. ; a ; To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs with curative intent; and b ; Where access to a health care facility is problematic. LIMITED USE BENEFITS - REVISED CRITERIA and myambutol.
Raloxifene online
Based on the available evidence, we make the following recommendations to our patients regarding the treatment and prevention of osteoporosis Table 3 ; . We advocate early detection and aggressive treatment to prevent osteoporosis. We recommend that bone densitometry be performed as part of the pretransplantation evaluation to assess the degree of bone loss before transplantation. After transplantation, we repeat the bone densitometry yearly for at least the first 2 years. In patients with decreased bone mineral density, we continue yearly bone densitometry. In patients with wellpreserved bone density, the densitometry can be repeated every 3 to 5 years. However, the scans are obtained earlier if the patient acquires new risks for bone loss. Patients with a T score of 1 to 2.5 in either the femur or the lumbar spine are offered lifestyle counseling. They are encouraged to quit smoking, adopt a high-calcium diet, and commence regular low-impact exercise. In our p rogram, lifestyle counseling is provided by the clinic nurses. In other centers, special multidisciplinary osteoporosis clinics have been created, which include dietitians, physical therapists, and pharmacists. For patients with!
Barrier for penetration of dissolution medium into HPMC gel and diffusion of drug out of that. It can be seen from the results of formulations F7-F9, when a polymer with higher capability to form a more viscous gel is placed either is placed in the core of the three-layer tablet F8 ; , or incorporated in one-layer F9 ; the drug release slows down the drug release. Table 3 shows the values of DE480 for different formulations. According to the concept of DE, formulations with more sustained action show smaller DE values. DE480 value for formulation F7 is 79.51, whereas for formulation F8 is equal to 47.6 which shows the effect of incorporation of HPMC in the core of the tablet and etoposide.
|
Medicine and are not referred to in this leaflet.
Woman may choose to spend her health plan allowance to pay for this test. The allowance is either 0 or 0, depending on what the employer chooses. Co-pay; amount of co-pay depends on the specifics of the policy Co-pay; amount of co-pay depends on the specifics of the policy and vepesid.
Anyqa any health questions and answers website what effects could a person expect to experience while taking the following prescription drugs.
HDL Other Code: PCS PAM ; PTA ; 2003 1 Category: Action. For Action: Chief Executives, NHS Boards, NHS Trusts, Spec Health Boards, State Hospital. For Information: Chief Executive HEBS: Members Scottish Partnership Forum. Responses Required? No. SEHD Contact: Ms Judith Ballantine 0131-244 3778 Email: Judith.Ballantine scotland.gsi.gov and famciclovir.
Missed dose if you miss a dose of this medicine and you are taking 1 dose daily, take the missed dose if you remember the same day.
Drug uses evista raloxifene ; is a prescription medicine used by women after menopause to treat or prevent a condition called osteoporosis and femara and raloxifene.
Soy Phytoestrogens, Raloxifene, and Endothelial Function in Postmenopausal Women: A Randomized, Placebo-Controlled, Crossover Trial. D. L. Katz, * M. A. Evans, * M. L. Hoxley, * V. Y. Njike, * H. Nawaz, * B. P. Comerford, * and P. M. Sarrel. * Yale Prevention Research Center, CT; Yale University School of Medicine, New Haven, CT. OBJECTIVE: To compare the effects of soy phytoestrogens and raloxifene on endothelial function in healthy, postmenopausal women. DESIGN: Randomized, double-blind, placebo-controlled crossover trial. Subjects n 22; mean age 58.5 y ; underwent endothelial function testing at baseline and after 6 wk of daily soy phytoestrogens 55 mg ; , raloxifene 60 mg ; , and placebo in random sequence with intervening 6-wk washout periods. Endothelial function was assessed as flow-mediated vasodilatation FMD ; of the brachial artery using high-resolution ultrasound; digital flux was measured with laser Doppler velocimetry. RESULTS: Baseline pretreatment ; FMD was essentially normal at 9.6% 6.4 ; . FMD did not change from baseline within any treatment group and no between-group differences were detected. FMD after treatment with soy, raloxifene, and placebo was 8.27% 7.7 ; , 10.28% 12.3 ; , and 9.5% 4.4 ; , respectively. Area-under-the-curve ratios showed no treatment differences for digital velocimetry. CONCLUSIONS: In this study of 22 healthy postmenopausal women, neither soy phytoestrogens nor raloxifene enhanced endothelial function. As measured in both the macro- and microcirculations, endothelial function was stable across treatments as were serum lipid values. These findings thus do not reveal a vasoprotective effect of either treatment. However, the cohort had relatively normal endothelial function at baseline. The phytoestrogen treatment in the study was convincingly without benefit. Although cholesterol fell with soy administration, it fell slightly more with placebo. FMD was similarly higher after placebo treatment than after 6 wk of soy. Further study is required to determine if particular subgroups of postmenopausal women derive vascular benefit from the use of selective estrogen receptor modulators or soy phytoestrogens.
Cheap raloxifene online
Health sections: home healthy living diseases & conditions health news groups & boards drug guide site index aging alternative medicine beauty birth control caregiving first aid & safety fitness nutrition & food oral care parenting pregnancy relationships smoking cessation stress travel health weight loss work issues adhd & add allergy arthritis asthma breast cancer cancer & chemotherapy children's health cholesterol cold & flu colon cancer depression diabetes digestive health headache & migraine heart & vascular health heartburn & gerd high blood pressure hiv & aids men's health mental health multiple sclerosis obesity osteoporosis sexual health & stds skin conditions sleep disorders stroke women's health » more topics encyclopedia provided by: healthwise a a-ag ah-ap aq-az b b-bg bh-bp bq-bz c c-cg ch-cp cq-cz d d-dg dh-dp dq-dz e e-eg eh-ep eq-ez f f-fg fh-fp fq-fz g g-gg gh-gp gq-gz h h-hg hh-hp hq-hz i i-ig ih-ip iq-iz j j-jg jh-jp jq-jz k k-kg kh-kp kq-kz l l-lg lh-lp lq-lz m m-mg mh-mp mq-mz n n-ng nh-np nq-nz o o-og oh-op oq-oz p p-pg ph-pp pq-pz q q-qg qh-qp qq-qz r r-rg rh-rp rq-rz s s-sg sh-sp sq-sz t t-tg th-tp tq-tz u u-ug uh-up uq-uz v v-vg vh-vp vq-vz w w-wg wh-wp wq-wz x x-xg xh-xp xq-xz y y-yg yh-yp yq-yz z z-zg zh-zp zq-zz 0-9 0-2 3-6 7-9 raloxifene for osteoporosis topic contents examples how it works why it is used how well it works side effects what to think about references credits email this article print this article examples raloxifene is taken in pill form every day and metronidazole.
VIII. Biological Basis for Raloxifene as a Breast Cancer Preventive.
Also maturing in this era will be the science of finetuning hormone requirements at the tissue level brought about by drugs regulating prohormone conversion to, or inactivation of, active hormone. Tissue-specific regulators of deiodinase, aromatase, 11-hydroxysteroid dehydrogenase HSD ; , and 5-reductase activities will emerge. Cardiac function in severe hypothyroid patients with coronary artery disease will be protected by cardiac-specific 3'-deiodinase inhibitors during thyroid hormone replacement. Tissue-specific 11-HSD inhibitors will protect against the catabolic, adipogenic, and diabetogenic effects of chronic glucocorticoid treatment. Several classes of centrally acting drugs controlling hypothalamic function will be available to battle obesity, following elucidation of the major appetite-regulating pathways and those regulating basal energy expenditure. Chimeric compounds harboring multiple properties are under active development.
Short instruction period required. Can be assembled with readily available equipment. Inexpensive. Portable. Non-electronic : No electricity supply is required. The test result is rapidly obtained. Highly reliable. Reliable during cardiac arrests. Reusable.
Tablet formulation. Double-layered tablets were prepared by direct compression. A physical blend of the polymers was mixed with mortar and pestle for 15 minutes. Then the mixture was compressed in a singlepunch 13-mm ; eccentric press Delfabro HPH 15, San 2 Francisco, Crdoba ; under 1500 kg cm for 5 seconds, resulting in a 2-mm-thick tablet. 1.
Women taking raloxifene had 36 percent fewer uterine cancers and 29 percent fewer blood clots than the women taking tamoxifen and efavirenz.
|
